hotspot -WSS

hotspot

author：fashion 2025-09-28 02:32:13 - browse：673

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA seeks to regulate lab

WSS

Francis Collins on trust in science and how Covid communications failed

Inequities make cancer less preventable for women: report

Ionis has late

WHO recommends dropping component of many flu vaccines

Prior authorization will have to move faster under new Biden rule

Covid vaccines: Private market messier than government rollout

hotspot

hotspot

focus

ChatGPT in medicine: STAT answers readers' burning questions

Inequities make cancer less preventable for women: report

The cancer drug shortage isn’t new — and neither are the solutions

Mindstrong's demise and the future of mental health care

Bright Health sells Medicare Advantage business to Molina

How the Dana

Walensky prepares to leave CDC — and Congress — behind

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Guidelines to prevent youth baseball injuries need more muscle

Parkinson’s finding may lead to tests and, someday, treatments

hotspot

Would Medicare drug price negotiations stall in a shutdown?

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Data show record exodus of life scientists from academia

Dewpoint Therapeutics lays off staff after losing partnerships

NIH director takes cautious approach to Biden drug pricing priority

Eli Lilly, Pfizer, and others want in on the online prescription market

hotspot

entertainment

focus

leisure time